Gilead Hits Mark With Second Long-Acting HIV PrEP Trial

The company stands a strong chance of winning approval for lenacapavir as a twice-yearly injectable drug for preventing HIV infection, though market challenges remain.

• Source: Shutterstock

Gilead Sciences, Inc. stands a strong chance of winning approval for its twice-yearly injectable HIV drug Sunlenca (lenacapavir) as pre-exposure prophylaxis (PrEP) for the prevention of HIV with positive results from a second Phase III registrational trial.

The drug maker said 12 September that results from the PURPOSE 2 study, comparing lenacapavir injected twice per year against...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas